Allspring Global Investments Holdings LLC Boosts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Allspring Global Investments Holdings LLC increased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 48.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,248 shares of the company's stock after acquiring an additional 5,655 shares during the period. Allspring Global Investments Holdings LLC's holdings in Hims & Hers Health were worth $536,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HIMS. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC grew its holdings in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Summit Securities Group LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $38,000. UMB Bank n.a. grew its holdings in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Hims & Hers Health by 165.4% in the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after purchasing an additional 961 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Friday, May 16th. The stock was sold at an average price of $58.40, for a total value of $7,482,616.80. Following the sale, the chief executive officer owned 89,311 shares in the company, valued at $5,215,762.40. The trade was a 58.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Chi sold 17,102 shares of Hims & Hers Health stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the sale, the insider owned 278,654 shares in the company, valued at $16,649,576.50. This represents a 5.78% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 670,250 shares of company stock worth $34,487,591. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded down $2.36 during trading on Friday, reaching $47.91. 18,925,676 shares of the company were exchanged, compared to its average volume of 23,898,503. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The company has a market capitalization of $10.72 billion, a P/E ratio of 69.44, a PEG ratio of 1.76 and a beta of 2.02. The stock's 50 day simple moving average is $53.68 and its two-hundred day simple moving average is $41.05.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the business posted $0.05 earnings per share. The firm's revenue was up 110.7% compared to the same quarter last year. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

HIMS has been the topic of several research analyst reports. Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. UBS Group set a $30.00 price objective on Hims & Hers Health in a report on Monday, June 23rd. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and an average price target of $39.58.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.